A high throughput 384-well plate assay of blood function in 60 III reactions with the fluorogenic thrombin substrate, boc-VPR-MCA, allowed for real-time monitoring of coagulation under a diverse set of reaction conditions. Using recalcified, citrated whole blood diluted 3-fold with corn trypsin inhibitor (to block Factor Xlla), addition of 0 to 13.8 pM of tissue factor (TF) reduced the time of maximal rate of thrombin production (Tmax) from 45 min to II min. Over this range ofTF,Tmax was reduced from 35 min to 6 min by co-addition of 10 nM convulxin to activate platelets via GPVI. The maximal rate of thrombin production at Tmax was not a function of exogenously-added TF,Va, or reVlla, but increased 30% with added convulxin. Addition of 0.07 to 0.7 pMTF along with convulxin produced small, but detectable reductions in Tmax: Addition of up Keywords Fluorescence, thrombin, kinetics, platelet factor 4 to 0.67 nM reVlla reducedT max by up to 53% in the range of 0.7 to 7 pM TF. Interestingly, platelet factor 4 (2.7 1lM) caused a prolongation ofT max from 45 min to 78 min at OTF,while protamine (1.8 IlM) reduced Tmax to 30 min at 0 TF. Finally, combinatorial reaction studies with exogenously-added ADp, histamine, fMLp,indomethacin, anti-CD 18, and fibrinogen revealed no unusual synergies amongst the agents, but demonstrated a striking procoagulant activity of added fibrinogen, due to protease contaminants in the "purified" fibrinogen. This high throughput approach allowed automated profiling of blood (50 reactions/ml of blood) to generate large data sets for testing cellular-proteomic kinetic models, screening drug interactions, and potentially monitoring subtle changes in the functional phenotype of a patient blood sample.
Introduction
Advances in robotic liquid handling and fluorescence plate reading allow the assembly of over 10 6 individual reactions for the purposes of high throughput screening (HIS) of combinatorial chemical libraries in well volumes as small as I to 10 ul., Similarly, protein microarrays, microfluidic devices, and Systems Biology analytical tools are beginning to find use in clinical research and diagnostics. As a reactive biological fluid, blood (and its fractions) is fully amenable to liquid handling and fluorogenic substrate probes for real-time monitoring of protease function (1, 2, 3, 4) , including rnicroarray reactions with nanoliter volumes (5) . Additionally, kinetic models of tissue factor-triggered clotting are quite advanced (6) (7) (8) , but do not incorporate aspects of intracellular metabolism. Unique to blood as a proteomic system, however, is the hemodynamic regulation of transport physics and receptor-mediated adhesion (7, 9, 10) . The time of maximum rate (T max) and the maximum rate (dF'/dt",.,J define the fastest rate of thrombin generation. well's lowest fluorescence (Fo), the data was normalized between 0 and I using F'(t) = (F(t)-Fo)/(Fmax-Fo) to help control well-to-well liquid handling and detection variation. Analysis of the normalized thrombin substrate conversion traces included extraction of: (a) the initiation time T, defined as the time whenF(T i ) = 1.03(Fo) or F'(T i ) = 0.03, (b) the time of maximum rate of thrombin production (Tmax); and (c) the maximum rate of thrombin production (dF' /d~ax) (Fig. I) . The rate of thrombin production for each point is determined by fitting a curve to the point in question (excluding the first and last data points) and its adjacent points, and determining the derivative at that point. T max and dF'/d~ax are determined when the derivative (dF'/dt) is maximal and does not necessarily correspond to the time when substrate is 50% consumed. The substrate hydrolysis rate is linearly dependent on [thrombin] only at low levels of conversion. T max and dF'/d~ax are data analysis tools to define when thrombin production becomes explosive. After Tmax, the derivative becomes zero due to substrate consumption and ample amounts of active thrombin may reside in the clotting sample. This was proven by addition of fresh substrate at 25 min beyond Tmaxthat was rapidly cleaved (data not shown). Statistical comparisons of the data were made using the unpaired Student's t-test.
Results
Tissue factor titration At each TF concentration, 12 separate wells were used to illustrate the variability in the coagulation reactions, especially when TF was not added. Without added TF ( Fig. 2A) , the precise time of onset of the propagation phase was highly variable. This extreme variability at 0 TF was not likely the result of small liquid handling errors « 3%), but rather the nature of the extreme nonlinear sensitivity of amplifying protease cascades to the initial trigger levels (see Discussion) and was observed time and again with multiple donors. Similarly, addition of 1.38 pM of TF (Fig. 2B ) did not produce any striking enhancement of clotting under these conditions, likely due to the action of antithrombin III or tissue factor pathway inhibitor (TFP!). In contrast, 2.08 pM TF caused a shortening of the initiation phase and the variability of the initiation times was reduced ( and dF'/dt",axo Control (white bars) contained only the factor Vila inherent in normal blood (-1.67 ng/mL). Recombinant factor Vila (reVlla) was also added to reactions at a final concentration of 6.67 ng/ml (black bars), 15.0 ng/ml (grey bars), and 31.7 ng/ml (striped bars). At low levels of tissue factor, there was little or no change in initiation time or time of maximum rate, but at intermediate tissue factor concentrations (2.08 pM and 2.77 pM, in particular), there was a graded enhancement of clotting with increasing reVlla. :E'
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cantly change initiation time, time of maximum rate, or the maximum rate (Fig. 4) . The activity off actor Va was verified by supplementation to factor V deficient plasma (data not shown).
From Figure 4 , we conclude that the enhancement of dF'/d1max due to convulxin stimulation (Fig. 3C ) was not likely due to increased release/generation of Va, but rather reflected the effect of elevated anionic phospholipids exposure on XaVa function. Recombinant factor Vila (reVIIa) is used by hemophiliacs to reduce bleeding episodes (23) . Normal VII levels are 500 ng/m1 with -1% as Vila (5 ng/mL). Increasing amounts of reVIIa (0, 6.67, 15.0, 31.7 ng/ml final concentration) were added to 3-fold diluted normal whole blood. With 3-fold dilute normal whole blood, the concentrations added correspond to normal (0 ng/m1 added), 5X, lOX, and 20X normal VIla (6.67, 15.0, and 31.7 ng/m1 reVlla, respectively). Procoagulant effects were only detected in the presence of added TF (Fig. 5) . At 0 or sub-picomolar concentrations of TF, T, was not significantly altered by increasing reVIla. However, at higher levels of TF, significant contributions to initiation time and time of maximum rate were seen at the highest reVIla concentration (31.7 ng/mL) beginning at 0.277 pM TF. Contributions at the interme- DO diate concentrations (6.67 and 15.0 ng/mL) were visible at 2.08 pM ofTF. At the highest TF concentration of 13.8 pM, the procoagulant effects of reVIIa was only statistically significant at the highest concentration of reVIla (31.7 ng/mL), with high TF concentration triggering strong blood coagulation and masking the effects of the intermediate reVIIa concentrations. For comparison, typical hemophiliac dosages at injection are about 1.261lg/ml which would yield an equivalence of -420 ng/ml or -251X normal VIla concentration in the well plate experiment with 3-fold diluted whole blood. The cationic protein Platelet Factor 4 (PF4) is a major release product of platelets (24) with less defined procoagulant and anticoagulant activities. TF titration demonstrated (Figs. 6A and 6B) that high concentrations of PF4 (black bars) had an overall slowing effect on thrombin production even at high TF concentrations (2.77 pM). Conversely, protamine (grey bars), another cationic protein and known complement activator (25) , enhanced the rate of clotting. Similar to reVila supplementation, increasing TF to high levels decreased the anticoagulant or procoagulant effects ofPF4 and protamine, respectively.
Lo, Diamond: High throughput coagulation assay Figure 7 : Effect of a combinatorial mixture of reaction modifiers on dotting kinetics without added TF. Individual components had a final concentration of 10 11MADP. 100 nM histamine, 10 nM fMLp, 100 11Mindomethacin, 10 Ilg/ml anti-CD 18, and 3 mg/ml fibrinogen. A procoagulant activity of added fibrinogen was easily detected, potentially due to protease or cofactor contaminants in the original fibrinogen. This technique demonstrated that the state of platelet activation at t = 0 does have an effect on the initiation phase (T}, propagation phase (TmoJ, and rate of maximal thrombin generation (elF'/dt'max) in a TF-titration assay, although the convulxin effects become small at the highest level of TF added. Activation of platelets with convulxin resulted in initiation times similar to that achieved by adding~0.28 pM TF without convulxin. If platelet activation with convulxin were to result in the exposure of an activity (cofactor or enzyme) and that activity were to be TF or TF-like in function, then the effect of that activity appears to be equivalent to sub-pM levels of TF. However, addition of anti-TF had no observed effect on T, in the absence of convulxin or TF addition (Fig. 8) . The maximal value of eIF'/dt is potentially a property set by the activated platelet. Since anti-IX significantly reduced T, and maximal
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elF' /dt, we conclude that the activated platelet makes the majority of its thrombin through IXa-VIlla. From the anti-IX experiment (Fig. 8) , it is clear that IXa was a critical "amplifier" in the assay since anti-IX was the only agent to reduce the maximal eIF'/dt in our experience.
The action of reVIIa was seen to have little effect on clotting in the absence of added TF, consistent with its use in hemophilia therapy. Also, the cationic PF4 had a significant delaying effect on thrombin generation by an unknown mechanism, potentially involving PF4 complexation with anionic sites on the activated platelet. However, protamine did not mimic the action of PF4 and had a potent enhancing effect on clotting, potentially through complement activation (25) . Also, "purified" human fibrinogen is a common reagent in hematological research. However its potential in promoting coagulation via seen in Fig. 3 are not adequately described by current models. Additionally, an automated algorithm in coagulation monitoring may have some future role in blood phenotyping as a patient ages or undergoes a therapeutic regimen. Another approach is to analyze the data via multifactor analysis to reveal crucial reactions, compounds, and reaction sets. This leads to the analysis of drug-drug interactions since drugs, new and old, can be combined and examined for their effects experimentally.
Future work in this area will study the effect of donor variability on the critical TF threshold as well as examine the effect of tissue factor pathway inhibitor (TFPI) concentration on the critical TF concentration. More specifically, we hope to gain a better understanding through TF-titration of the competition between TFPI inhibition of factor Xa and the protection from inhibition that factor Va provides when it complexes with factor Xa.
The objective ofthis research was to establish a quantitative understanding of blood stability, and then determine how interactions in blood affect this stability. We have developed a technique to quickly scan and profile coagulation interactions. The power of this technique lies in the number of experiments that can be run in parallel using a single donor's blood. Different combinations of chemical species can be scanned against blood over a range of tissue factor concentrations and convulxin levels.
